摘要
目的:评价单用诺和龙(瑞格列奈)与其联合二甲双胍治疗初发2型糖尿病的有效性和安全性。方法:选择初发2型糖尿病(T2DM)患者120例,分为诺和龙组联合二甲双胍(治疗组)60例和单用二甲双胍组(对照组)60例,治疗3个月,评估疗效及副作用的发生情况。结果:2组治疗后的空腹血糖、餐后2h血糖及糖化血红蛋白均比用药前明显降低(P<0.05),但体重与治疗前无显著性差异(P>0.05)。治疗组餐后2h血糖(8.55±2.13)mmol/L明显低于对照组(9.48±3.12)mmol/L(P<0.05),但空腹血糖及糖化血红蛋白变化二组间差别无显著性意义(P>0.05)。安全性分析表明,患者对诺和龙有较好的耐受性,尤其是低血糖的发生率明显降低。结论:诺和与二甲双胍联合治疗T2DM是安全有效的。
Objective： To compare the therapeutic efficacy of administration of Novolon （repaglinide） with and without metformin in the patients with Type 2 diabetes mellitus （T2DM） primarily diagnosed. Methods： 120 cases with T2DM were divided repaglinide ＋ metformin （treatment group） 60 cases and metformin（control group） for 3-- month-- treatment. Results： The contents of Fasting plasma glucose（FPG）, 2 hours postprandialplasma glucose（2hPG）, HbAlc were decreased significantly in both of the groups after three months of treatment （P〈0.05）, but weight （W） （P〉0. 05）. The contents of 2hPG in treatment group （8.55±2. 13）mmol/L were lower than that in control group（9. 48 ±3. 12）mmol/L（P〈0.05）. No hypoglycemia was observed. Conclusions： The repaglinide with metformin is effective and safe in treating T2DM
出处
《内蒙古中医药》
2010年第1期10-11,共2页
Inner Mongolia Journal of Traditional Chinese Medicine
关键词
瑞格列奈
二甲双胍
2型糖尿病
应用
Repeglinide
Metformin
Type 2 diabetesmellitus
Application
